Mpox Death in Mice Prevented by Antibodies Targeting A35 Protein
Antibodies from a person who had previously been infected with mpox provides full protection from severe illness and death in mice.| GEN - Genetic Engineering and Biotechnology News
Eschewing the traditional model of financing biotech startups milestone to milestone to support a lead asset, Treeline Biosciences’ well-funded pipeline is comprised of multiple complementary programs. Select investors have supported the approach of Treeline, which said it has raised more than $1.1 billion to date. The post Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic appeared first on MedCity News.| MedCity News
A high-volume platform for rapidly constructing and characterizing antibodies, called oPool+ display, could potentially speed vaccine and therapeutic development. The post High-Throughput Antibody Platform May Transform Therapeutic Discovery appeared first on GEN - Genetic Engineering and Biotechnology News.| GEN – Genetic Engineering and Biotechnology News
Women of reproductive age seem to be less susceptible to CKD than men, but the molecular mechanisms were not well understood. Paola Romagnani, MD, PhD, speaks with GEN about the estrogen-driven protective effect against CDK. The post Estrogen Signaling Impacts Kidney Cell Regeneration with Links to Preeclampsia appeared first on GEN - Genetic Engineering and Biotechnology News.| GEN – Genetic Engineering and Biotechnology News
Early-stage findings suggest that blocking the ABHD18 gene may restore mitochondrial function and improve heart function in Barth syndrome, a rare, often fatal genetic disorder that lacks effective therapies. The post Preclinical Data Spotlights Gene with Therapeutic Potential for Barth Syndrome appeared first on GEN - Genetic Engineering and Biotechnology News.| GEN – Genetic Engineering and Biotechnology News
RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures. Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors. Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an over...| InnovationMap
Antibodies from a person who had previously been infected with mpox provides full protection from severe illness and death in mice.| GEN - Genetic Engineering and Biotechnology News
As the biotech and biopharma industries strive to develop more precise, personalized and effective therapies for complex diseases, researchers require access to deeper insights from cells, tissues and proteins. Spatial biology, the study of biomolecules and cells within their native tissue microenvironment, along with other advanced imaging techniques, is enabling scientists to better visualize, map… The post Spatial biology in focus: A 12-image deep dive appeared first on Research & Develo...| Research & Development World
In GEN’s flagship virtual event, The State of Biotech, outstanding research and business leaders from industry and academia will discuss the latest research developments, innovations, new technologies, and convulsive regulatory changes that are reshaping the world of biotech.| GEN - Genetic Engineering and Biotechnology News
The one-drug-many-indications model has steadily grown in popularity since the early 2000s. But Irvine, California–headquartered Tarsus Pharmaceuticals is aiming to bring the model to XDEMVY (lotilaner), an antiparasitic drug that first won FDA-approval in dogs. After licensing lotilaner from Elanco, Tarsus won FDA approval for the drug, under the trade name XDEMVY, for the treatment… The post Q2 net sales reach $100M for Tarsus’ XDEMVY, a potential treatment for Lyme and malaria rooted...| Drug Discovery and Development
Bispecific antibodies (BsAbs) are redefining the landscape of therapeutic design, offering dual-target precision that conventional antibodies can’t match. These specially engineered antibodies bind to either two different antigens or two distinct sites on the same antigen. BsAbs form a powerful new class of therapy which has caused excitement among the drug development community due to… The post Bispecific antibodies: The next generation of precision therapeutics appeared first on Drug ...| Drug Discovery and Development
The movement of epithelial cells during wound healing is mediated by the endoplasmic reticulum, which senses the curvature of wound gaps.| GEN - Genetic Engineering and Biotechnology News
VantAI's AI platform will accelerate programmable protein interaction therapies across Halda's cancer and immunology indications.| GEN - Genetic Engineering and Biotechnology News
Researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.| GEN - Genetic Engineering and Biotechnology News
As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward...| HotSpot Therapeutics
Learn how Deep Science Ventures’ zero-data approach tackles biotech’s early funding challenges to speed innovation and reduce risk.| Labiotech.eu
NATO Innovation Fund backs Portal Biotech in its first biotech move. What does this signal for strategic investment in healthcare innovation?| Labiotech.eu
Liu’s research focuses on the discovery of small molecules for human proteins, as well as the functional characterization of these proteins in physiological and disease contexts.| wertheim.scripps.ufl.edu
Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center appeared first on Drug...| Drug Discovery and Development
Half of glioblastoma patients have a subtype that doesn’t respond to any approved cancer drugs. A new experimental treatment from The Wertheim UF Scripps Institute shows promise in mouse studies. Clinical trials are coming soon.| The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Tec...
Researchers at the Korea Research Institute of Standards and Science (KRISS) have created a new nanomaterial that can simultaneously detect and treat cancer using multiple approaches. In laboratory tests with mice, the gold-iron particles enabled real-time tumor imaging while delivering targeted treatment through heat, chemical reactions and immune system activation. Published in the Chemical Engineering… The post Korean team reports all-in-one cancer nanomedicine in pre-clinical studies ap...| Drug Discovery and Development
Alex Tropsha is part of a multi-million dollar, federally funded project using machine learning to identify new uses for existing drugs.| UNC Research Stories
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Massively Parallel Ribosome Profiling (MPRP) enables rapid identification of viral proteins without the need to grow live viruses.| GEN - Genetic Engineering and Biotechnology News
British life sciences startup Kiin Bio has secured an oversubscribed €1.9 million pre-Seed investment round to launch their Virtual Scientist Platform for| EU-Startups
The once pioneering DNA test company 23andMe is now a penny stock that has filed for bankruptcy. Its CEO Anne Wojcicki is also stepping down.| Drug Discovery and Development
His paper was called “the miracle result.” But it never turned into an Alzheimer’s treatment. Now, four former Genentech senior scientists and executives allege that an internal review in 2011 discovered the paper had been based on fabricated research — and that Marc Tessier-Lavigne kept the results of the review from becoming public. He denies the allegations.| The Stanford Daily
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which The post A New Wave of Therapeutic Innovation Through Targeting Transcription Factors appeared first on LifeSciVC.| LifeSciVC
"Discovering new medicines is challenging work that requires the expertise of many. There are real synergies for our scientists and students as we build collaboration among departments," said Matthew Disney, Ph.D., chair of The Wertheim UF Scripps chemistry department.| wertheim.scripps.ufl.edu
Children born with a damaged gene needed for healthy brain development, SYNGAP1, experience seizures, sensory processing disorders, difficulty speaking, intellectual disability, and autism-like behaviors. It’s a condition without any treatments, one that’s hard both on parents and children, said Gavin Rumbaugh, Ph.D., a neuroscientist at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation &…| wertheim.scripps.ufl.edu
In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one...| HotSpot Therapeutics
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development
PubMiner AI aims to help researchers in the biomedical domain overcome the challenges in automatic knowledge extraction from large volumes of scientific publications. The post Advancing Automatic Knowledge Extraction with PubMiner AI appeared first on Ontotext.| Ontotext
Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health.| Labiotech.eu
Dr. Hendrik Luesch’s new joint appointment will expand UF’s natural products research to one of the world’s prime areas for marine biodiversity.| pharmacy.ufl.edu
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.| Labiotech.eu
A new computational screening system using AI could lead to more efficient, cost-effective and expansive search for novel therapeutic drugs.| Promega Connections
At HotSpot, we’re harnessing insights from nature by pinpointing specialized protein on/off switches, or pockets, called “natural hotspots.” To date,...| HotSpot Therapeutics
Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used...| HotSpot Therapeutics
At HotSpot, we are committed to building something we believe is truly distinctive, setting ourselves apart from our peers in...| HotSpot Therapeutics
Every company has a culture, either by design or default. From our inception in 2016, we wanted to create a...| HotSpot Therapeutics
The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...| HotSpot Therapeutics
